Board of Directors


Laurence Rulleau Ph.D.

Chairman of the Board of Directors

Dr. Rulleau, Ph.D is a partner at CTI Life Sciences Fund, a life sciences venture capital fund.  Dr. Rulleau has served as a life sciences analyst covering the Canadian life sciences sector for more than 10 years. As an analyst, she covered over 100 life sciences companies including scientific due diligence, market and competitive analysis.  Dr. Rulleau was ranked the #1 Canadian life sciences analyst by the Starmine survey and #1 independent analyst by Brendon Wood survey. Dr. Rulleau has been involved in numerous mergers and acquisitions as well as IPOs.

Previously Dr. Rulleau was CEO of HLA-G Technologies, a biotechnology start-up based in France and also served as Vice President Business Development of Univalor, the technology transfer office of Montreal’s university and affiliated schools. Under her responsibility at Univalor completed more than 40 industry licenses and launched 8 start-up companies.

Dr. Rulleau has a Ph.D. from Université de Montréal earned at the Montreal Clinical Research Institute.


Benoit Bouche Ph.D. AMP

President and CEO

Benoit spent over 30 years on growing healthcare businesses and, solving fast growth-related issues as an entrepreneur, advisor and deal maker, or independent board member.

He has an unrivaled experience in pharmaceutical outsourcing. He created and led an advisory firm, a central lab, and a clinical project monitoring unit, the three business units of what became the leading clinical stage CRO in Continental Europe in the late nineties with over 400 people, mainly located in France, Italy, and Germany. He is a board member at Mapi Group, then a late phase CRO with few tens of people and today the world leader in late phase patient-centered research with 800 people and revenues north of €100m. He also is a managing partner at Trans Hit Bio, the reference human biological samples procurement for biomarker development purposes CRO.

Benoit has a dual scientific (PharmD Pharmacy 1984; PhD Pharmaceutical Sciences/Biotechnology 1986) and business (Advanced Management Program Harvard Business School 2002) education. His professional background enabled him to get to know in details all aspects of a healthcare venture stage company and to favor understanding and collaboration between scientists and business persons.

In the investment banking field, he has been the head of Puilaetco (since acquired by KBC) research team between 1998 and 2002, instrumental in the emergence of a fund investing in innovative healthcare companies and of what became the reference M&A healthcare team in Europe (Bryan Garnier). He sourced and led the execution of over 40 M&A transactions and financing rounds for biotechnology and medical device companies, or CROs. He is an advisor to IMAP, a 400 M&A professionals network with a presence in over 40 countries, ranked since years in the worldwide top 5 Thomson Financials league tables in the small and mid-markets.

Max Fehlmann ​Ph.D., MBA

​President and CEO
Cancer Research Society

Max has joined the Cancer Research Society as President and CEO in January 2017. The Cancer Research Society is a national not-for-profit organization whose sole mission is to fund research on all types of cancer. Since its founding in 1945, it has been helping Canadian researchers and physicians to better understand the causes of cancer. The Society contributes to the development of effective treatments that improve patients’ quality of life and helps to protect Canadians’ health through cancer prevention.

Formerly President, CEO and co-founder of NEOMED, Max was leading the entire NEOMED initiative. He was in charge of the strategic planning and corporate development of both NEOMED and the NEOMED Institute.

Before being at NEOMED Max was President and CEO of CQDM (a pre-competitive consortium in drug discovery regrouping major pharmaceutical companies and public institutions). During the last 35 years, the career of Max encompassed the 3 fundamental domains involved in NEOMED, from academic research (Forgarty International Fellow at Harvard Medical School, Professor of Pharmacology at the University of Nice in France, Research Director at INSERM in France, with over 200 peer reviewed publications), SME management (founder and CEO of Aster Biotechnologies in France and CEO of Chronogen in Montreal) and Pharma R&D (VP R&D for Zambon Group in Italy for all pre-clinical, clinical and licensing activities of the group worldwide as well as founder of Z-cube, a corporate Venture fund linked to Zambon Group).

Max obtained his PhD in Biochemistry from Université Laval in 1975, a Doctorat ès Sciences from the University of Nice (France) in 1981 and an MBA from HEC-CPA at Sophia Antipolis (France) in 1992. He received numerous scientific and business awards during his career in Europe and in Canada.

​Donald Olds ​M.Sc., MBA

​President and Chief Executive Officer
NEOMED Institute

Donald is in charge of the strategic planning, the corporate development, and the integration of all components of the NEOMED Institute in the local, national, and international R&D communities.

Prior to be named President and CEO of the NEOMED Institute in January 2017, Donald was Chief Operating Officer of Telesta Therapeutics Inc. a publicly-listed biotechnology company (TSX: TST). At Telesta, he was responsible for finance and investor relations, manufacturing operations, business development, human resources and strategy.  Over the course of his three-year tenure, he led a successful U.S. financing to fund the U.S. commercial launch of Telesta’s bladder cancer therapeutic and negotiated a significant ex-U.S. License for the same asset.  In October 2016, he led the process that led to the successful sale of Telesta Therapeutics to a larger public biotechnology company.

Prior to Telesta Therapeutics, he was President and CEO of Presagia Corp., a private Montreal-based software development company focused on developing innovative solutions for workforce management for large US-based organizations.  In this role, he led several successful private financings and helped build Presagia’s reputation for delivering quality decision support software solutions to complex organizations.

Before joining Presagia, he worked for almost 9 years as Chief Financial Officer and Chief Operating Officer of Aegera Therapeutics, where he was responsible for clinical operations, business development, finance, and Mergers and Acquisitions. During his tenure, Aegera raised over $100 Million in growth capital, initiated 5 clinical development programs, acquired a private oncology company, and executed multiple licensing transactions, one of which was recognized as the largest preclinical licensing transaction ever closed in Canada.

Prior to Aegera Therapeutics, Donald was Chief Financial Officer of Mediatrix Telecom where he was responsible for operations, finance and manufacturing and led the technology investment banking practice of TD Securities in Quebec.

Donald is currently Chairman of Oxfam Quebec and Director of Presagia Corp. and has extensive past corporate governance experience serving on the boards of private and public for-profit and not-for-profit organizations.  He holds an MBA (Finance & Strategy) and M.Sc. (Renewable Resources) from McGill University.  He has travelled extensively and worked in Senegal, West Africa for two years as a foreign expert on a Canadian development project.  He lives in Montreal with his family.

Michael J. Berendt Ph.D.

Life Sciences Industry Consultant

Michael has served as CEO and Chief Scientist of Telesta Therapeutics Inc. and AegeraTherapeutics Inc.  He held Managing Director positions with Research Corporation Technologies and AEA Investors, where he led investments in life sciences companies.  Michael served as Senior Vice President of Research for the Bayer Corporation and a Group Director of Drug Discovery at Pfizer, Inc.

During this time he was responsible for managing drug discovery including the Bayer team that discovered Nexavar, a cancer therapeutic.  Michael is a director of Waters Corporation and the NEOMED Institute.  He has served on the board of Alethia, Onyx, Myriad Genetics, and Trillium Therapeutics.  Michael is a graduate of Ohio Dominican College, has a Master’s degree from Miami University, and a Ph.D. in medical microbiology and immunology from Drexel University.  Past awards included grants from the Cancer Research Institute, American Cancer Society, and Leukemia Society of America.

Paul Buron CPA

Executive Vice-President, Government Mandates and Programs Management

Paul Buron was appointed Executive Vice-President, Government Mandate and Program Management in November 2017.

Mr. Buron has more than 30 years’ experience in financial management, risk management and business strategies. From 2006 until he joined Investissement Québec, he served as Executive Vice President and Chief Financial Officer of the Business Development Bank of Canada (BDC). Until 2016, he was also in charge of risk management for BDC. In 2011-2012, he held the position of Interim Executive Vice President, Financing and Consulting for one year in addition to his other responsibilities.

Mr. Buron is a member of the boards of directors of the NEOMED Institute and Oxfam Québec and mentors with the Association of Québec Women in Finance mentoring program.